Overall, it is likely that decreased Keap1-Nrf2 signaling in mPFC and hippocampus is associated with anhedonia-like phenotype in rats with neuropathic pain, and that Nrf2 activators, including SFN, have therapeutic potential in patients with neuropathic pain-associated anhedonia. Here, NFE2L2 is linked to neuropathic pain.